This bill requires the federal Agency for Toxic Substances and Disease Registry to commission an independent assessment of how PFAS chemicals affect human health and develop clinical guidance for doctors treating patients exposed to these substances. The agency has 60 days after the bill becomes law to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine or another qualified organization to conduct the initial assessment and recommendations, which must be completed within two years. The agency must then issue updated clinical guidance within five years and refresh it every five years thereafter, or more frequently if scientific evidence warrants it. The guidance will be posted on the agency's website and shared with state and local health authorities and healthcare professionals to ensure medical providers have current information for treating PFAS-related health conditions. This legislation affects patients exposed to PFAS contamination, healthcare providers, and public health officials seeking the latest evidence-based treatment recommendations.